Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy (CIPN) (EA-EX CIPN)

I. Rationale and Synergistic Mechanisms Chemotherapy-induced peripheral neuropathy (CIPN) represents a highly prevalent and debilitating neurotoxic syndrome in cancer survivors treated with taxanes or platinum-based agents. Clinically, it presents as persistent symmetrical paresthesia, burning sensations, neuropathic pain, and significant proprioceptive deficits in the extremities. While conventional pharmacological management frequently yields suboptimal efficacy or introduces intolerable central nervous system adverse effects, this protocol investigates a non-pharmacological, integrative medical strategy combining Electro-Acupuncture (EA) with progressive multi-modal exercise training.

The scientific rationale predicates on a dual-pathway synergistic mechanism: EA serves as an internal neuro-modulatory intervention that delivers stable micro-currents to deep acupoints, thereby stimulating the endogenous opioid system, down-regulating systemic and local pro-inflammatory cytokines, optimizing microcirculation, and facilitating axonal myelin sheath regeneration. Concurrently, the progressive exercise training serves as an external functional rehabilitation mechanism. By driving neuromuscular retraining, exercise reinforces cortical-peripheral functional connectivity and enhances dynamic postural control, thereby counteracting the structural proprioceptive deficits unaddressed by acupuncture alone.

II. Technical Standardization of Interventions The therapeutic protocol is rigorously standardized over an 8-week duration, leveraging an integrated in-hospital and digital home-based framework to guarantee a uniform total dosage of three intervention sessions per week for all participants.

A. Electroacupuncture (EA) Protocol: Acupuncture is delivered by certified clinical practitioners targeting predefined bilateral acupoints to elicit the characteristic "de-qi" sensation (soreness, numbness, distension). Stimulus is applied via an electrical stimulator configured to a dense-disperse wave frequency of 2/100 Hz for a fixed duration of 20 minutes.

1. Upper Extremity Acupoints: Quze (PC3), Neiguan (PC6), and Daling (PC7).
2. Lower Extremity Acupoints: Zusanli (ST36), Sanyinjiao (SP6), Taixi (KI3), and Taichong (LR3).
3. Frequency Allocation: The protocol's frequency is determined by the in-hospital attendance cohorts. Participants under Tier 1 are allocated to receive 1 in-hospital session/week, whereas participants under Tier 2 are allocated to receive 2 in-hospital sessions/week.

B. Progressive Multi-Modal Exercise Training (Experimental Group Only): Immediately following the termination of EA, participants engage in 30 minutes of supervised, progressive balance and neuromuscular exercises. The exercise intensity is strictly regulated within a moderate range, corresponding to a Rating of Perceived Exertion (RPE) of 11 to 14. The dynamic regimen incorporates:

1. Multi-directional single-leg stepping tasks.
2. Single-leg stance coupled with active trunk rotation control.
3. Dynamic balance training integrated with synchronous upper extremity proprioceptive tasks and visual tracking.
4. Progressive lunge ambulation combined with axial trunk rotations.
5. Unilateral cross-knee touch balance-strength maneuvers.

C. Digital Home Support and Dosage Synchronization: To equalize the cumulative therapeutic volume across different baseline severity cohorts, a structured home support system is deployed via a dedicated intelligent digital platform:

1. Tier 1 : Completes 1 in-hospital session and 2 home-based sessions per week.
2. Tier 2 : Completes 2 in-hospital sessions and 1 home-based session per week. Home compliance is enforced via customized QR codes linking to institutional instructional videos for standardized exercise execution and complementary acupressure. Participants maintain a structured electronic "Home Exercise Diary" to log adherence, task completion frequencies, and subjective post-exercise fatigue.

III. Statistical Analysis Considerations To accommodate clinical attrition common among oncology patient populations undergoing post-chemotherapy surveillance, the total sample size incorporates an anticipated 15% drop-out rate to secure evaluable final data datasets. The longitudinal therapeutic effects across multiple discrete intervals (Baseline, Week 4, and Week 8) will be primarily evaluated using Repeated Measures Analysis of Variance (RM-ANOVA) to isolate inter-group and intra-group variances. Subgroup analyses will be systematically executed based on baseline symptom stratifications to detect severity-specific treatment responses, with Pearson's correlation coefficients utilized to ascertain the specific mathematical relationship between home exercise compliance and functional balance increments.